# AIDS 2020 Track B abstract submission categories

| Track B – Clinical research
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Course of HIV disease</strong></td>
</tr>
<tr>
<td>B1</td>
</tr>
<tr>
<td>B2</td>
</tr>
<tr>
<td>B3</td>
</tr>
<tr>
<td><strong>Diagnostic and monitoring tools</strong></td>
</tr>
<tr>
<td>B4</td>
</tr>
<tr>
<td>B5</td>
</tr>
<tr>
<td>B6</td>
</tr>
<tr>
<td>B7</td>
</tr>
<tr>
<td>B8</td>
</tr>
<tr>
<td>B9</td>
</tr>
<tr>
<td><strong>Co-infections (including opportunistic infections)</strong></td>
</tr>
<tr>
<td>B10</td>
</tr>
<tr>
<td>B11</td>
</tr>
<tr>
<td>B12</td>
</tr>
<tr>
<td>B13</td>
</tr>
<tr>
<td>B14</td>
</tr>
<tr>
<td><strong>Co-morbidities and complications (including those related to ART)</strong></td>
</tr>
<tr>
<td>B15</td>
</tr>
<tr>
<td>B16</td>
</tr>
<tr>
<td>B17</td>
</tr>
<tr>
<td>B18</td>
</tr>
<tr>
<td>B19</td>
</tr>
<tr>
<td>B20</td>
</tr>
<tr>
<td>B21</td>
</tr>
<tr>
<td>B22</td>
</tr>
<tr>
<td>B23</td>
</tr>
<tr>
<td>B24</td>
</tr>
<tr>
<td>B25</td>
</tr>
<tr>
<td>B26</td>
</tr>
<tr>
<td>B27</td>
</tr>
<tr>
<td>B28</td>
</tr>
<tr>
<td>B29</td>
</tr>
<tr>
<td><strong>Antiretroviral therapies in adults</strong></td>
</tr>
<tr>
<td>B30</td>
</tr>
<tr>
<td>B31</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td>B32</td>
</tr>
<tr>
<td>B33</td>
</tr>
<tr>
<td>B34</td>
</tr>
<tr>
<td>B35</td>
</tr>
<tr>
<td>B36</td>
</tr>
<tr>
<td>B37</td>
</tr>
<tr>
<td>B38</td>
</tr>
</tbody>
</table>

**Other strategies and therapies**

<table>
<thead>
<tr>
<th>B39</th>
<th>Therapeutic vaccine trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>B40</td>
<td>Cure interventions</td>
</tr>
<tr>
<td>B41</td>
<td>Complementary and traditional medicines</td>
</tr>
<tr>
<td>B42</td>
<td>Nutrition</td>
</tr>
</tbody>
</table>

**Clinical issues specific to gender**

<table>
<thead>
<tr>
<th>B43</th>
<th>Sex-specific issues of ART efficacy, adverse reactions and complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>B44</td>
<td>Pregnancy (clinical management issues and pharmacokinetics)</td>
</tr>
<tr>
<td>B45</td>
<td>Contraception</td>
</tr>
<tr>
<td>B46</td>
<td>Menopause</td>
</tr>
</tbody>
</table>

**Clinical issues specific to paediatric and adolescent HIV**

<table>
<thead>
<tr>
<th>B47</th>
<th>Diagnosis of HIV disease in paediatric and adolescent populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>B48</td>
<td>Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B49</td>
<td>Drug formulations for infants and children</td>
</tr>
<tr>
<td>B50</td>
<td>Clinical trials in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B51</td>
<td>ARV management strategies in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B52</td>
<td>Cure strategies in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B53</td>
<td>Adherence in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B54</td>
<td>Opportunistic infections in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B55</td>
<td>TB/HIV co-infection in paediatric and adolescent populations (including treatment and prevention)</td>
</tr>
<tr>
<td>B56</td>
<td>HIV complications and co-morbidities in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B57</td>
<td>HIV-associated co-infections and malignancies in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B58</td>
<td>Behavioural health outcomes in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B59</td>
<td>Mental health and neurocognition in paediatric and adolescent populations</td>
</tr>
<tr>
<td>B60</td>
<td>HIV-exposed uninfected children</td>
</tr>
<tr>
<td>B61</td>
<td>Transition of adolescents into adult care</td>
</tr>
</tbody>
</table>

**Clinical issues specific to key populations and vulnerable populations**

<table>
<thead>
<tr>
<th>B62</th>
<th>Clinical issues in men who have sex with men</th>
</tr>
</thead>
<tbody>
<tr>
<td>B63</td>
<td>Clinical issues in sex workers</td>
</tr>
<tr>
<td>B64</td>
<td>Clinical issues in transgender people</td>
</tr>
<tr>
<td>B65</td>
<td>Clinical issues in people who use drugs</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>B66</td>
<td>Clinical issues in other vulnerable populations, including unstable settings (migrants) and incarcerated settings</td>
</tr>
<tr>
<td>B67</td>
<td>Ethical considerations related to clinical research with key populations and other vulnerable populations</td>
</tr>
<tr>
<td><strong>COVID-19</strong></td>
<td></td>
</tr>
<tr>
<td>B68</td>
<td>Use of HIV-related antiviral agents in COVID-19 prevention and treatment</td>
</tr>
<tr>
<td>B69</td>
<td>Clinical manifestations and features of COVID-19 and HIV co-infection</td>
</tr>
</tbody>
</table>